Snrnp70 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SNRNP70 (U1-70K) is a core component of the U1 small nuclear ribonucleoprotein (snRNP), the spliceosome complex responsible for recognizing the 5' splice site during pre-mRNA splicing. As a member of the spliceosome, SNRNP70 plays a fundamental role in RNA processing, and its dysfunction has been implicated in neurodegenerative diseases including ALS and frontotemporal dementia.
| SNRNP70 Protein |
|---|
| Protein Name | U1 snRNP 70kDa |
| Alternative Names | U1-70K, SNRNP70 |
| Gene | SNRNP70 |
| UniProt ID | P08621 |
| Chromosomal Location | 19q13.33 |
| Protein Class | RNA-binding protein |
| Subcellular Localization | Nucleus (nucleoplasm, spliceosome) |
| Protein Family | SR family proteins |
| Molecular Weight | ~70 kDa |
SNRNP70 contains several functional domains:
- RNA recognition motif (RRM1)
- Proline-rich region
- RS domain (arginine/serine repeats)
- Additional RNA-binding domains
- Protein interaction surfaces
- Localization signals
¶ C-terminal Domain
- RS domain for spliceosome targeting
- Phosphorylation sites
- Protein-protein interaction motifs
SNRNP70 is essential for spliceosome function:
- Component of the U1 snRNP particle
- Associates with U1 snRNA (U1-70K, U1-A, U1-C)
- Recruited to 5' splice sites
- Binds 5' splice site consensus (GU)
- Initiates spliceosome assembly (E complex)
- Coordinates with U2AF and U2 snRNP
- Participates in spliceosome activation (A complex)
- Remains associated through splicing reaction
- Released after splicing completion
- Regulates tissue-specific splicing patterns
- Important for neuronal-specific exons
- Dysregulation affects neuronal function
SNRNP70 is implicated in ALS pathogenesis:
Splicing Dysregulation:
- Aberrant splicing patterns in ALS
- Loss of U1 snRNP function
- Accumulation of unspliced transcripts
RNA Toxicity:
- GGGGX repeat expansions interfere with splicing
- Sequestration of SNRNP70
- Disruption of RNA homeostasis
TDP-43 Pathology:
- TDP-43 aggregates in 97% of ALS
- TDP-43 regulates SNRNP70 splicing
- Reciprocal relationship with splicing defects
- Similar splicing defects to ALS
- TDP-43 pathology links both diseases
- U1 snRNP dysfunction in brain
- Alternative splicing alterations in AD brain
- Changes in spliceosome composition
- Impaired RNA processing
- SNRNP70 splicing alterations
- SMN complex deficiency affects snRNP assembly
- Therapeutic targeting of splicing
SNRNP70 is ubiquitously expressed:
- Antisense oligonucleotides: Correct splicing patterns
- Small molecules: Modulate spliceosome function
- Gene therapy: Restore proper splicing
- Targeting RNA toxicity
- Enhancing spliceosome function
- TDP-43 normalization strategies
The study of Snrnp70 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tao & Wu, U1 snRNP and ALS (2015) - Trends in Neurosciences
- Laggerbauer & Krummhaar, U1 snRNP function in disease (2016) - Trends in Cell Biology
- Kapeli et al., TDP-43 and splicing in ALS (2016) - Nature Communications
- Lagier-Tourenne et al., ALS RNA metabolism (2010) - Trends in Neurosciences
- Prusti & Singh, SNRNP70 in disease (2022) - Neurobiology of Aging
- Wang et al., Spliceosome targeting in ALS (2019) - Nature Methods
- H上午 et al., U1 snRNP in FTD (2021) - Brain
- Cooper et al., RNA toxicity in neurodegeneration (2009) - Neuron